<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A 55-year-old man suffered a cutaneous relapse of an LMP1-positive follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> after treatment with antithymocyte globulin and <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> A (CSA) for a <z:hpo ids='HP_0012115'>hepatitis</z:hpo>-associated aplastic <z:hpo ids='HP_0001903'>anaemia</z:hpo> (AA) </plain></SENT>
<SENT sid="1" pm="."><plain>Rituximab was not effective, so CSA was tapered off </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0002665'>Lymphoma</z:hpo> masses did not regress but AA relapsed </plain></SENT>
<SENT sid="3" pm="."><plain>A second remission of both <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and AA was achieved with high-dose <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, but the patient died of a bilateral <z:hpo ids='HP_0002090'>pneumonia</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>The relationships between immunosuppression, <z:mp ids='MP_0001799'>viral</z:mp> reactivation and <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumour growth</z:e> are discussed </plain></SENT>
<SENT sid="5" pm="."><plain>The use of rituximab and lamivudine in immunodepressed patients is also commented </plain></SENT>
</text></document>